BChE
Butyrylcholinesterase (BChE, EC 3.1.1.8) is a cholinesterase family enzyme that hydrolyzes a broad range of choline esters and other ester-containing substrates, contributing to cholinergic regulation as well as xenobiotic detoxification processes[1][2]. BChE is widely distributed in human tissues and plasma, where it participates in cholinergic transmission, ester metabolism, and the neutralization of toxic compounds including organophosphates and carbamates[1]. Mechanistically, BChE functions as a hydrolytic enzyme that can buffer acetylcholine metabolism when acetylcholinesterase (AChE) activity is reduced, thereby influencing cholinergic homeostasis[2]. In disease contexts, increasing evidence links BChE to neurodegenerative disorders, particularly Alzheimer’s disease (AD), where BChE activity and expression become more prominent during disease progression and are associated with late-stage cholinergic dysfunction[3][4]. Experimental studies therefore consider BChE an important therapeutic target and biomarker candidate for AD-related research[3][4]. Compared with the closely related isoform AChE, which primarily terminates synaptic acetylcholine signaling, BChE exhibits broader substrate specificity, distinct tissue distribution, and a stronger role in drug metabolism, detoxification, and non-neuronal physiological processes[1][2]. For experimental applications, selective BChE inhibitors are widely used to investigate cholinergic mechanisms and have been developed as pharmacological tools for evaluating therapeutic strategies in neurodegenerative disease models, with high selectivity over AChE considered a key design objective[3][4].
References:
- [1]. Hajimohammadi S, et al. New views on physiological functions and regulation of butyrylcholinesterase and potential therapeutic interventions. Front Mol Biosci. 2025 Jun 19;12:1625318. [Content Brief]
- [2]. Jovičić SM. Enzyme ChE, et al. Enzyme ChE, cholinergic therapy and molecular docking: Significant considerations and future perspectives. Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241289013. [Content Brief]
- [3]. Brus B, et al. Discovery, biological evaluation, and crystal structure of a novel nanomolar selective butyrylcholinesterase inhibitor. J Med Chem. 2014 Oct 9;57(19):8167-79. [Content Brief]
- [4]. Zhou Y, et al. Discovery of Selective Butyrylcholinesterase (BChE) Inhibitors through a Combination of Computational Studies and Biological Evaluations. Molecules. 2019 Nov 20;24(23):4217. [Content Brief]
All Product Categories
-
BChE Related Products (229)
Related Products (229)
-
Thunberginol C
0 ImagesCat. No.: HY-N1151CAS No.: 147517-06-4Thunberginol C is an orally active, selective, and non-competitive inhibitor of AChE and BChE, with IC50 values of 41.96 and 42.36 μM, respectively. Thunberginol C exerts cytoprotective, pro-collagen type I restorative, MMP-1 inhibitory, hyaluronic acid restorative, anti-photoaging effects in skin cells. Thunberginol C exerts neuroprotective, anxiolytic, TNF-α inhibitory, neuroinflammation inhibitory, and oxidative stress inhibitory effects. Thunberginol C can be used for the research of Alzheimer’s disease, UVB-induced skin photoaging, allergic reactions, oral bacterial infections, and stress-induced anxiety.
-
BChE-IN-53
0 ImagesCat. No.: HY-W1058380CAS No.: 25870-73-9BChE-IN-53 is a butyrylcholinesterase (BChE) inhibitor with an IC50 value of 119.0 μM and is inactive against α-glucosidase. BChE-IN-53 can be used for the research of alzheimer's disease, type 2 diabetes mellitus.
-
7-Methoxytacrine
0 ImagesCat. No.: HY-W049312CAS No.: 5778-80-3Synonyms: 7-MEOTA7-Methoxytacrine (7-MEOTA) is an inhibitor of human acetylcholinesterase (hAChE) with an IC50 value of 10 μM, and can be used for the research of Alzheimer's disease (AD).
-
ZINC12613047
0 ImagesCat. No.: HY-113905CAS No.: 1069521-64-7ZINC12613047 is a selective BChE inhibitor with an IC50 of 0.021 μM against huBChE. ZINC12613047 can be used for the research of Alzheimer's disease.
-
Demeton-S
0 ImagesCat. No.: HY-W332450CAS No.: 126-75-0Demeton-S is an organophosphate insecticide. Demeton-S inhibits butyrylcholinesterase and acetylcholinesterase activity.
-
Trichlorfon ethyl
0 ImagesTrichlorfon ethyl is an analog of Trichlorfon (HY-B1220), as well as an inhibitor of Butyrylcholinesterase and Bacillus subtilis Esterase. Trichlorfon ethyl acts as a prenatal brain growth inhibitor, causing mild reductions in total brain weight, medulla oblongata weight and tectum weight in newborn guinea pigs, without affecting cerebellar weight. Trichlorfon ethyl does not induce severe prenatal brain hypoplasia in guinea pig offspring. Trichlorfon ethyl can be used in studies related to brain hypoplasia.
-
Anabasamine
0 ImagesCat. No.: HY-116041CAS No.: 20410-87-1
-
Ganstigmine
0 ImagesCat. No.: HY-183403CAS No.: 457075-21-7Synonyms: CHF 2819 free baseGanstigmine (CHF 2819 free base) is a potent, orally active, blood-brain barrier-permeable acetylcholinesterase (AChE) inhibitor, with an IC50 value of 65 nM against human AChE, 310 nM against human butyrylcholinesterase (BChE), and 5.12 μM against Torpedo californica AChE. Ganstigmine increases extracellular acetylcholine levels in the brain of rodents without altering the concentrations of other neurotransmitters, stimulates cholinergic transmission, and induces the release of soluble non-amyloidogenic amyloid precursor protein. Ganstigmine exhibits neuroprotective activity independent of cholinesterase inhibition, prevents neuronal death, alleviates β-amyloid-induced neurodegeneration, rescues cholinergic neuron loss, and reverses Scopolamine (HY-N0296)-induced amnesia and memory deficits. Ganstigmine shows cholinesterase inhibition-independent neuroprotective effects against growth factor deprivation and Aβ25-35 toxicity. Ganstigmine can be used in research on Alzheimer's disease, cholinergic dysfunction, and neuroprotection.
